Business Wire

Avinor Selects Thales to Deploy Norway’s Next-Generation Nationwide Unmanned Traffic Management System

9.12.2024 10:00:00 EET | Business Wire | Press release

Share

This strategic partnership with Avinor, the Norwegian air navigation service provider and airport operator, will enable the deployment of Norway’s next-generation nationwide Unmanned Traffic Management system. This collaboration represents a major step forward in Norway’s airspace management, combining innovation with strict regulatory compliance. It also signifies a key milestone for Thales in the integration of AstraUTM, a recently acquired leader in cutting-edge UTM software development.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209180613/en/

Drones flying in Norway, image generated by AdobeFireFly, December 2024 (Photo: Thales)

With its newly released product Topsky - UAS powered by AstraUTM, Thales will provide a safe and scalable digital platform for automated UTM and future AAM (Advanced Airspace Mobility). This system will efficiently manage air traffic in the vicinity of airports and metropolitan, suburban, and regional areas, offering capabilities such as compliance monitoring, authorisation management, real-time decision-making, continuous airspace surveillance, automated conflict resolution, and rapid response to dynamic conditions.

Ensuring safety and compliance in Norwegian skies

Avinor’s new UTM system aims to provide essential services for various stakeholders, including drone operators, air traffic service providers (ATSP), government agencies, and other key players in Norway in relation to the low altitude airspace management. The system will meet regulatory standards as specified in Implementing Regulation (EU) 2021/664, alongside the Acceptable Means of Compliance and Guidance Material for U-space management, ensuring that all services meet the highest standards of safety and operational transparency.

This UTM system will integrate safe, efficient and predictable access services such as the Common Information Service (CIS) and U-space Service Provider (USSP) provisions, ensuring complete regulatory compliance in U-space designated airspaces.

Enabling efficient UAS operations at scale nationwide

Through the implementation and management of a nationwide UTM system, Norway will benefit from robust unmanned traffic management solutions that support the diverse requirements of both civilian and governmental stakeholders. The system will deliver advanced real-time data sharing, streamlined and automated airspace access, and enhanced situational awareness to enable operations at scale in Norway’s dynamic airspace environment for all operators in the manned and unmanned airspace.

"We are honored to collaborate with Avinor to bring this nationwide UTM system to life in Norway, prioritising safety, innovation, and, naturally, regulatory alignment. Together with Avinor, we embrace the development of BVLOS (Beyond Visual Line of Sight) services in non-segregated airspaces, enabling technologies that make it simple and economical to perform safe, repeatable and scalable commercial UAS operations. Our UTM solutions, recently enhanced with AstraUTM, a Thales company, reflect Thales’ commitment to advancing airspace management and setting the foundation for safe and integrated air mobility," said Christian Rivierre, Vice-President Airspace Mobility Solutions, Thales.

"At Avinor, we are proud to be an active contributor in developing uncrewed aviation in Norway. Partnering with Thales on this next-generation UTM system reflects our dedication to advancing uncrewed operations in Norwegian airspace. This system will support Avinor’s role in ensuring the safe and efficient integration of drones, providing oversight, and managing airspace responsibly. We are excited to work with Thales as a strategic partner to deliver a solution that benefits all airspace users and supports air traffic services in managing drone operations," statedMats Bye Gjertsen, Vice-President Avinor Drone Programme.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies specialized in three business domains: Defence & Security, Aeronautics & Space, and Cyber & Digital.

It develops products and solutions that help make the world safer, greener and more inclusive.

The Group invests close to €4 billion a year in Research & Development, particularly in key innovation areas such as AI, cybersecurity, quantum technologies, cloud technologies and 6G.

Thales has close to 81,000 employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.

About Avinor

Avinor is a wholly-owned state limited company under the Norwegian Ministry of Transport and Communications and is responsible for 43 state-owned airports.

Avinor has taken a leading role in reducing climate gas emissions from the aviation industry, including the development of electric aircrafts and supplying sustainable jet-biojetfuel.

Avinor provides safe and efficient travels for around 50 million passengers annually, half of which travel to and from Oslo Airport.

Over 3000 employees are responsible for planning, developing and operating an efficient airport and air navigation service. Avinor is financed via airport charges and commercial sales. The air navigation services is organized as subsidiary wholly-owned by Avinor. Avinor's headquarter is in Oslo.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241209180613/en/

Contacts

Press Contact:
Thales Media Relations
pressroom@thalesgroup.com

Avinor Media Relations
presse@avinor.no

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye